HealthSnap, Inc. announced that it has received $4.999999 million in funding from OPKO Health, Inc., W5 Group, LLC, Florida Funders, LLC, MacDonald Ventures, Hard Facts Ab and other investor
November 09, 2021
Share
HealthSnap, Inc. announced that it has received 3,378,378 series B preferred stock at an issue price of $1.48 per share for gross proceeds of $4,999,999.44 in a round of funding led by new investor OPKO Health, Inc. on November 10, 2021. The transaction included participation from new investors W5 Group, LLC, 6nine26, returning investors Florida Funders, LLC, MacDonald Ventures, and Hard Facts Ab. The company has raised $12.2 million in funding till date. The preferred shares will be convertible into common shares at $1.48 per share. The dividend will be non-cumulative, and shares will be non-redeemable. The round is raised at a post-money valuation of $22.2 million.
The company announced that it has 8,000,000 series B preferred stock as authorized series B preferred stock.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
HealthSnap, Inc. announced that it has received $4.999999 million in funding from OPKO Health, Inc., W5 Group, LLC, Florida Funders, LLC, MacDonald Ventures, Hard Facts Ab and other investor
OPKO HEALTH, INC. 
